FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200442435> ?p ?o ?g. }

• W4200442435 endingPage "S1428" @default.
• W4200442435 startingPage "S1428" @default.
• W4200442435 abstract "BackgroundTIGIT is a novel immune checkpoint present on activated T cells and NK cells; inhibition of TIGIT may further amplify the inhibition of the PD-L1/PD-1 pathway. CITYSCAPE (NCT03563716) is the first randomised Phase II study of an anti-TIGIT antibody; the combination of TA showed clinically meaningful improvement in ORR and PFS compared with PA in patients (pts) with metastatic PD-L1+ NSCLC. Here we present updated PFS, OS, and PROs.MethodsEligible pts with chemotherapy-naïve PD-L1+ (TPS ≥1% by local or central 22C3 IHC pharmDX assay) locally advanced, unresectable or metastatic NSCLC were randomised 1:1 to receive TA (T 600 mg IV + A 1200 mg IV) or PA (A 1200 mg IV) every 3 weeks until disease progression or loss of clinical benefit. The EORTC QLQ-C30 was administered at baseline and throughout study treatment. Co-primary endpoints: investigator-assessed ORR and PFS. Additional endpoints: DOR, OS, safety, association of tumour PD-L1 expression levels with clinical outcomes and PROs from the ITT population.ResultsTable: LBA2ITTPD-L1 TPS >=50%PATAPATAn68672929ORR, % (95% CI)20.6 (10.2, 30.9)38.8 (26.4, 51.2)24.1 (6.8, 41.4)69.0 (50.4, 87.5)mDOR, mo (95% CI)10.7 (6.0, 18.8)17.6 (9.1, 26.1)8.2 (5.6, 10.4)15.7 (9.1, NE)mPFS, mo (95% CI)3.9 (2.7, 4.5)5.6 (4.2, 10.4)4.1 (2.1, 6.8)16.6 (5.5, 22.3)HR (95% CI)0.62* (0.42, 0.91)0.29† (0.15, 0.53)mOS, mo (95% CI)14.5 (9.6, 20.4)23.2 (14.1, 31.5)12.8 (4.7, 24.2)NE (30.3, NE)HR (95% CI)0.69* (0.44, 1.07)0.23† (0.10, 0.53)*Stratified; †Unstratified. NE, non-evaluable. Open table in a new tab ConclusionTA continues to provide a clinically meaningful benefit in pts with metastatic NSCLC, driven by the PD-L1+ TPS ≥50% subgroup. TA has a manageable safety profile consistent with PD-L1/PD-1 inhibitors. Patients on TA maintained global health status and functioning and showed improvements in dyspnea and pain. Durable response and encouraging OS continue to support evaluating TA in metastatic PD-L1-high NSCLC.Clinical trial identificationNCT03563716.Editorial acknowledgementMedical writing support for the development of this abstract, under the direction of the authors, was provided by Abigail Robertson, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by F. Hoffmann-La Roche Ltd.DisclosureB.C. Cho: Financial Interests, Personal, Advisory Board: KANAPH Therapeutic Inc., Brigebio therapeutics, Cyrus therapeutics, Guardant Health, Joseah BIO; Financial Interests, Personal, Member of the Board of Directors: Gencurix Inc., Interpark Bio Convergence Corp.; Financial Interests, Personal, Full or part-time Employment: Yonsei University College of Medicine; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc., Gencurix Inc., Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp.; Financial Interests, Personal, Royalties: Champions Oncology; Financial Interests, Institutional, Research Grant: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp.; Financial Interests, Personal, Advisory Role: Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines; Other, Personal, Other, Founder: DAAN Biotherapeutics. D. Rodriguez-Abreu: Financial Interests, Personal, Other, honoraria: Roche, AstraZeneca, Bristol-Myers Squibb, MSD, Eli Lilly, Pfizer, and Novartis; Financial Interests, Institutional, Invited Speaker, travel support: Roche, Bristol-Myers Squibb, MSD and Novartis. M. Hussein: Financial Interests, Personal, Advisory Role: IntegraConnect, Coherus Biosciences, Athenex, Karyopharm Therapeutics, BMS, AstraZeneca, Mirati Therapeutics, Exelixis. N. Secen: Non-Financial Interests, Personal and Institutional, Principal Investigator: Institute for Pulmonary Diseases of Vojvodina, Serbia. D. Kim: Financial Interests, Institutional, Research Grant: Alpha Biopharma, Amgen, Astrazeneca/Medimmune, Boehringer-Ingelheim, Daiichi-Sankyo, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, Chong Keun Dang,Bridge Bi; Financial Interests, Personal, Other, Travel support for advisory board meeting attendance: Amgen, Daiichi-Sankyo. E. Huang: Financial Interests, Personal, Full or part-time Employment: Roche Products Ltd. N. Patil: Financial Interests, Personal, Full or part-time Employment: Genentech. M. Huang: Financial Interests, Personal, Full or part-time Employment: Roche. X. Wen: Financial Interests, Personal, Full or part-time Employment: Roche Genentech. D. Mendus: Financial Interests, Personal, Full or part-time Employment: Genentech; Financial Interests, Personal, Stocks/Shares: Genentech. T. Hoang: Financial Interests, Personal, Full or part-time Employment: Roche Genentech; Financial Interests, Personal, Stocks/Shares: Roche Genentech. R.D. Meng: Financial Interests, Personal, Full or part-time Employment: Genentech; Financial Interests, Personal, Stocks/Shares: Genentech. M.L. Johnson: Financial Interests, Institutional, Research Grant: AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, Boehringer Ingelheim, Calithera Biosciences, Checkpoint Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi; Financial Interests, Personal, Advisory Role: Achilles Therapeutics, Bristol-Myers Squibb, Editas Medicine, Eisai, G1 Therapeutics, Ideaya Biosciences, Lilly Association of Community Cancer Centers. All other authors have declared no conflicts of interest. BackgroundTIGIT is a novel immune checkpoint present on activated T cells and NK cells; inhibition of TIGIT may further amplify the inhibition of the PD-L1/PD-1 pathway. CITYSCAPE (NCT03563716) is the first randomised Phase II study of an anti-TIGIT antibody; the combination of TA showed clinically meaningful improvement in ORR and PFS compared with PA in patients (pts) with metastatic PD-L1+ NSCLC. Here we present updated PFS, OS, and PROs. TIGIT is a novel immune checkpoint present on activated T cells and NK cells; inhibition of TIGIT may further amplify the inhibition of the PD-L1/PD-1 pathway. CITYSCAPE (NCT03563716) is the first randomised Phase II study of an anti-TIGIT antibody; the combination of TA showed clinically meaningful improvement in ORR and PFS compared with PA in patients (pts) with metastatic PD-L1+ NSCLC. Here we present updated PFS, OS, and PROs. MethodsEligible pts with chemotherapy-naïve PD-L1+ (TPS ≥1% by local or central 22C3 IHC pharmDX assay) locally advanced, unresectable or metastatic NSCLC were randomised 1:1 to receive TA (T 600 mg IV + A 1200 mg IV) or PA (A 1200 mg IV) every 3 weeks until disease progression or loss of clinical benefit. The EORTC QLQ-C30 was administered at baseline and throughout study treatment. Co-primary endpoints: investigator-assessed ORR and PFS. Additional endpoints: DOR, OS, safety, association of tumour PD-L1 expression levels with clinical outcomes and PROs from the ITT population. Eligible pts with chemotherapy-naïve PD-L1+ (TPS ≥1% by local or central 22C3 IHC pharmDX assay) locally advanced, unresectable or metastatic NSCLC were randomised 1:1 to receive TA (T 600 mg IV + A 1200 mg IV) or PA (A 1200 mg IV) every 3 weeks until disease progression or loss of clinical benefit. The EORTC QLQ-C30 was administered at baseline and throughout study treatment. Co-primary endpoints: investigator-assessed ORR and PFS. Additional endpoints: DOR, OS, safety, association of tumour PD-L1 expression levels with clinical outcomes and PROs from the ITT population. ResultsTable: LBA2ITTPD-L1 TPS >=50%PATAPATAn68672929ORR, % (95% CI)20.6 (10.2, 30.9)38.8 (26.4, 51.2)24.1 (6.8, 41.4)69.0 (50.4, 87.5)mDOR, mo (95% CI)10.7 (6.0, 18.8)17.6 (9.1, 26.1)8.2 (5.6, 10.4)15.7 (9.1, NE)mPFS, mo (95% CI)3.9 (2.7, 4.5)5.6 (4.2, 10.4)4.1 (2.1, 6.8)16.6 (5.5, 22.3)HR (95% CI)0.62* (0.42, 0.91)0.29† (0.15, 0.53)mOS, mo (95% CI)14.5 (9.6, 20.4)23.2 (14.1, 31.5)12.8 (4.7, 24.2)NE (30.3, NE)HR (95% CI)0.69* (0.44, 1.07)0.23† (0.10, 0.53)*Stratified; †Unstratified. NE, non-evaluable. Open table in a new tab *Stratified; †Unstratified. NE, non-evaluable. ConclusionTA continues to provide a clinically meaningful benefit in pts with metastatic NSCLC, driven by the PD-L1+ TPS ≥50% subgroup. TA has a manageable safety profile consistent with PD-L1/PD-1 inhibitors. Patients on TA maintained global health status and functioning and showed improvements in dyspnea and pain. Durable response and encouraging OS continue to support evaluating TA in metastatic PD-L1-high NSCLC. TA continues to provide a clinically meaningful benefit in pts with metastatic NSCLC, driven by the PD-L1+ TPS ≥50% subgroup. TA has a manageable safety profile consistent with PD-L1/PD-1 inhibitors. Patients on TA maintained global health status and functioning and showed improvements in dyspnea and pain. Durable response and encouraging OS continue to support evaluating TA in metastatic PD-L1-high NSCLC." @default.
• W4200442435 created "2021-12-31" @default.
• W4200442435 creator A5000034553 @default.
• W4200442435 creator A5004370741 @default.
• W4200442435 creator A5005836249 @default.
• W4200442435 creator A5007151673 @default.
• W4200442435 creator A5008838901 @default.
• W4200442435 creator A5012285379 @default.
• W4200442435 creator A5014543023 @default.
• W4200442435 creator A5020451529 @default.
• W4200442435 creator A5023818678 @default.
• W4200442435 creator A5027946288 @default.
• W4200442435 creator A5049294543 @default.
• W4200442435 creator A5051157616 @default.
• W4200442435 creator A5055964030 @default.
• W4200442435 creator A5068913222 @default.
• W4200442435 creator A5071875932 @default.
• W4200442435 creator A5074511773 @default.
• W4200442435 creator A5079426717 @default.
• W4200442435 creator A5080580204 @default.
• W4200442435 creator A5081591010 @default.
• W4200442435 date "2021-12-01" @default.
• W4200442435 modified "2023-10-16" @default.
• W4200442435 title "LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC" @default.
• W4200442435 doi "https://doi.org/10.1016/j.annonc.2021.10.217" @default.
• W4200442435 hasPublicationYear "2021" @default.
• W4200442435 type Work @default.
• W4200442435 citedByCount "16" @default.
• W4200442435 countsByYear W42004424352022 @default.
• W4200442435 countsByYear W42004424352023 @default.
• W4200442435 crossrefType "journal-article" @default.
• W4200442435 hasAuthorship W4200442435A5000034553 @default.
• W4200442435 hasAuthorship W4200442435A5004370741 @default.
• W4200442435 hasAuthorship W4200442435A5005836249 @default.
• W4200442435 hasAuthorship W4200442435A5007151673 @default.
• W4200442435 hasAuthorship W4200442435A5008838901 @default.
• W4200442435 hasAuthorship W4200442435A5012285379 @default.
• W4200442435 hasAuthorship W4200442435A5014543023 @default.
• W4200442435 hasAuthorship W4200442435A5020451529 @default.
• W4200442435 hasAuthorship W4200442435A5023818678 @default.
• W4200442435 hasAuthorship W4200442435A5027946288 @default.
• W4200442435 hasAuthorship W4200442435A5049294543 @default.
• W4200442435 hasAuthorship W4200442435A5051157616 @default.
• W4200442435 hasAuthorship W4200442435A5055964030 @default.
• W4200442435 hasAuthorship W4200442435A5068913222 @default.
• W4200442435 hasAuthorship W4200442435A5071875932 @default.
• W4200442435 hasAuthorship W4200442435A5074511773 @default.
• W4200442435 hasAuthorship W4200442435A5079426717 @default.
• W4200442435 hasAuthorship W4200442435A5080580204 @default.
• W4200442435 hasAuthorship W4200442435A5081591010 @default.
• W4200442435 hasBestOaLocation W42004424351 @default.
• W4200442435 hasConcept C121608353 @default.
• W4200442435 hasConcept C126322002 @default.
• W4200442435 hasConcept C142724271 @default.
• W4200442435 hasConcept C143998085 @default.
• W4200442435 hasConcept C204787440 @default.
• W4200442435 hasConcept C27081682 @default.
• W4200442435 hasConcept C2775949291 @default.
• W4200442435 hasConcept C2777701055 @default.
• W4200442435 hasConcept C2779118045 @default.
• W4200442435 hasConcept C2780057760 @default.
• W4200442435 hasConcept C71924100 @default.
• W4200442435 hasConceptScore W4200442435C121608353 @default.
• W4200442435 hasConceptScore W4200442435C126322002 @default.
• W4200442435 hasConceptScore W4200442435C142724271 @default.
• W4200442435 hasConceptScore W4200442435C143998085 @default.
• W4200442435 hasConceptScore W4200442435C204787440 @default.
• W4200442435 hasConceptScore W4200442435C27081682 @default.
• W4200442435 hasConceptScore W4200442435C2775949291 @default.
• W4200442435 hasConceptScore W4200442435C2777701055 @default.
• W4200442435 hasConceptScore W4200442435C2779118045 @default.
• W4200442435 hasConceptScore W4200442435C2780057760 @default.
• W4200442435 hasConceptScore W4200442435C71924100 @default.
• W4200442435 hasLocation W42004424351 @default.
• W4200442435 hasOpenAccess W4200442435 @default.
• W4200442435 hasPrimaryLocation W42004424351 @default.
• W4200442435 hasRelatedWork W3031115858 @default.
• W4200442435 hasRelatedWork W3049330696 @default.
• W4200442435 hasRelatedWork W3137394727 @default.
• W4200442435 hasRelatedWork W3194633883 @default.
• W4200442435 hasRelatedWork W3212751604 @default.
• W4200442435 hasRelatedWork W4210323056 @default.
• W4200442435 hasRelatedWork W4220718484 @default.
• W4200442435 hasRelatedWork W4308399075 @default.
• W4200442435 hasRelatedWork W4327545673 @default.
• W4200442435 hasRelatedWork W4362541535 @default.
• W4200442435 hasVolume "32" @default.
• W4200442435 isParatext "false" @default.
• W4200442435 isRetracted "false" @default.
• W4200442435 workType "article" @default.